Clinical Trial Update: Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy [NA]

View source ↗

Summary

The trial evaluating celecoxib to prevent ovarian cancer in BRCA1/BRCA2 mutation carriers undergoing prophylactic oophorectomy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• CELEBREX (Celecoxib)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: brca1 Mutation Carrier, brca2 Mutation Carrier | NA | Status: WITHDRAWN